21 results about "Photophobia" patented technology

An ophthalmic imaging system provides an automatic focus mechanism based on the difference of consecutive scan lines. The system also provides of user selection of a focus point within a fundus image. A neural network automatically identifies the optic nerve head in an FA or ICGA image, which may be used to determine fixation angle. The system also provides additional scan tables for multiple imaging modalities to accommodate photophobia patients and multi-spectrum imaging options.

The present invention provides a low-concentration atropine nanoemulsion, its preparation method and application, belonging to the field of pharmaceutical technology. In the present invention, atropine is used as the main drug, and oil and surfactant are successfully used to encapsulate atropine in the oil phase, solving the problem of poor stability of atropine aqueous solution, realizing the slow release of atropine in the eye, improving the bioavailability of the drug, reducing adverse reactions such as mydriasis, photophobia, and dry eye, having good biocompatibility, and overcoming the problem of irritation to the eye caused by too high local concentration of ordinary eye drops. The nanoemulsion and lower-concentration nanoemulsion of the present invention have high bioavailability, have the effect of effectively delaying the development of myopia, have high safety, small side effects, and good application prospects.

The invention discloses near-vision-preventing health-care liquid and a preparation method thereof. The near-vision-preventing health-care liquid is prepared from the following raw materials in parts by weight: 8-12 parts of cornu bubali, 1-3 parts of borneol, 4-6 parts of xanthophyll, 8-12 parts of radix angelicae sinensis, 8-12 parts of radix paeoniae rubra, 6-10 parts of folium mori, 12-18 parts of semen plantaginis, 8-12 parts of flos chrysanthemi, 12-18 parts of cortex fraxini and 12-18 parts of semen cassiae. According to years of medicine practicing experience and in combination with the theory of traditional Chinese medicine, natural traditional Chinese medicine plants with the effects of clearing liver and improving vision, clearing away heat and toxic materials, promoting blood circulation, dissipating blood stasis and relieving pain, clearing away heat and drying dampness and promoting blood circulation are selected; the traditional Chinese medicine composition can relieve eyestrain, eye dryness, eye acerbity, red eyes, blurred vision, dark circles, ghosting, photophobia, tear against wind, eye discomfort and other symptoms caused by overuse of eyes, the effect is remarkable, the effect taking speed is high, and myopia development is delayed by relieving eyestrain and preventing myopia; in addition, the preparation process is simple, easy to operate and convenient for expanded production.

This invention discloses a lutein-infused massage and care eye ointment containing precious Chinese medicinal herbs, free of eight major allergens, and suitable for all ages. Each tube contains 10 grams. The formula uses lutein as its core ingredient, combined with artificial musk, bear bile powder, pearl powder, ginseng, and Ganoderma lucidum, along with eye-protecting ingredients such as wolfberry, chrysanthemum, cassia seed, and buddleja flower. It is supplemented with sodium hyaluronate and vitamin B6, using medical-grade hypoallergenic petrolatum as a base. The ointment is strictly free of eight major allergens, making it safe and gentle, suitable for people aged 3 to 100. This invention features a simple process, can be industrially produced, and can effectively relieve eye fatigue, dry eyes, itchy eyes, bloodshot eyes, dark circles, eye bags, wrinkles, photophobia, and tearing in the wind, among other sub-healthy eye problems. It has extremely high market application and health care value.

The invention discloses a jerusalem artichoke composition for relieving asthenopia and application thereof. Comprising 40-60 parts of jerusalem artichoke leaf and jerusalem artichoke peel mixed extract and 10-15 parts of inulin. The jerusalem artichoke leaf and jerusalem artichoke peel mixed extract is obtained by extracting functional components through enzymolysis, microwave and other processes. The invention further provides a product for relieving asthenopia. The product comprises 40-60 parts of jerusalem artichoke leaf and jerusalem artichoke peel mixed extract, 10-15 parts of inulin, 0.5-1 part of angelica sinensis powder, 0.2-0.6 part of safflower powder, 6-10 parts of Borojo powder and 6-10 parts of green plum powder. The jerusalem artichoke leaves and the jerusalem artichoke barks are used as raw materials and are combined with the inulin to be used as the composition for relieving asthenopia, and the composition is safe, free of toxic and side effects and capable of effectively maintaining the moist ocular surface, adjusting the contraction and relaxation capacity of ciliary muscles and adjusting intestinal flora; the asthenopia problems such as dry eyes, photophobia and aching pain can be effectively relieved.

The invention discloses a novel ophthalmic medicine and a preparation method thereof.The novel ophthalmic medicine is prepared from semen cassiae, glossy privet fruit, chrysanthemum, Chinese yam, schisandra chinensis, mint, ginger, fructus lycii, astragalus membranaceus, coptis chinensis, angelica sinensis, codonopsis pilosula, pearl powder, poria cocos, radix curcumae and other traditional Chinese medicinal materials, and the preparation method comprises the steps of mixing the medicinal materials, decocting, filtering, filling and the like, before use, cleaning and disinfection are needed, the decoction time is 1-2 hours, the decoction temperature is 100-120 DEG C, a filter is made of gauze and filter paper, after filtration, standing and re-filtration are needed, and finally, an ultraviolet germicidal lamp and high-temperature disinfection are used for disinfecting a container, so that sanitation and safety of the medicine are ensured. The medicine contains various traditional Chinese medicinal materials, and has a very good health-care effect on myopia, presbyopia, astigmatism, amblyopia, photophobia and tear induced by wind.

The invention discloses a traditional Chinese medicine composition for treating perimenopausal dry eyes and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine formulas. The traditional Chinese medicine composition for treating the perimenopausal dry eye comprises herba epimedii, prepared rehmannia root, rhizoma anemarrhenae, cortex phellodendri, radix paeoniae alba, angelica sinensis, radix bupleuri, poria cocos and honey-fried licorice root. The traditional Chinese medicine composition for treating perimenopausal dry eye, namely the kidney-warming dry eye formula, has the functions of warming kidney, nourishing yin, soothing liver and strengthening spleen, can effectively improve perimenopausal symptoms such as dry eye, photophobia, asthenopia, foreign body sensation, burning sensation, soreness and weakness of waist and knees, dysphoria, irritability, hot sweating, insomnia, amnesia and the like of patients with perimenopausal dry eye, improves the estrogen level, and has the efficacy of treating perimenopausal dry eye. The ocular surface inflammatory response is inhibited, and the tear film stability is improved.

Disclosed is an apparatus and method for combating light sensitivity, or photophobia, for people with low vision. Both the apparatus and method filter particular wavelengths of light associated with photophobia. This filtering is achieved while maintaining a luminance that is acceptable to the user and that maintains contrast. The apparatus of the disclosure is a mechanical filter that can be applied over an electronic screen. The method utilizes software and a filtering module associated with either the CPU or GPU of a computer. The filtering module processes a video signal by eliminating certain targeted wavelengths of light.

To provide methods, systems and apparatus for reducing frequency and / or severity of photophobic responses or for modulating circadian cycles.SOLUTION: An optical filter may reduce the frequency and / or severity of photophobic responses or modulate circadian cycles by controlling light exposure of cells in a human eye in specific wavelengths, such as 480 nm and 590 nm, and a visual spectral response of the human eye. The optical filter may disrupt the isomerization of melanopsin in the human eye thereby reducing the availability of an active isoform, whereas the attenuation of light weighted across the action potential spectrum of the active isoform attenuates the phototransduction cascade leading to photophobic responses. In one embodiment, an optical filter may be configured to transmit less than a first amount of light at specific wavelengths, and to transmit more than a second amount of light weighted across the visual spectral response.SELECTED DRAWING: Figure 6

The purpose of the present invention is to provide an ophthalmic lens capable of reducing photophobia among more users when worn by a visually allergic user. This ophthalmic lens contains a dye, in which the dye contains a specific dye having a maximum absorption wavelength in the wavelength range of 400-510 nm, the maximum absorption coefficient of the specific dye in the wavelength range of 550-780 nm is 1 / 5 or less of the absorption coefficient at the maximum absorption wavelength of the specific dye, and Ta represents the average transmittance of the ophthalmic lens in the wavelength range of 430-480 nm, and Ta represents the average transmittance of the ophthalmic lens in the wavelength range of 430-480 nm. In a wavelength of 430-480 nm, the transmittance of the ophthalmic lens every 5 nm is in the range of Ta + / -y, and when the average transmittance of the ophthalmic lens at a wavelength of 550-780 nm is represented by Tb, Tb is greater than Ta. Wherein y is a value represented by formula (1). In the formula (1), y = (100%-Ta) * 0.1, wherein the unit of Ta, Tb and y is%.

Keratoconjunctivitis sicca is a general term of a plurality of diseases which are accompanied by eye discomfort and (or) ocular surface tissue lesion characteristics and are caused by tear quality or quantity abnormality or dynamic abnormality caused by any reason, and belongs to the field of chronic keratoconjunctivitis in western medicine. The common symptoms comprise eye dryness, easy fatigue, eye itching, foreign body sensation, burning pain, secretion viscosity, wind afraid, photophobia, lacrimation and external stimulation sensitivity; the two eyes of a patient with serious diseases in the later stage are red and swollen, hyperemia and keratinization, corneal epithelium exfoliation and filament adhesion exist, keratoconjunctival lesion can be caused if the patient is injured for a long time, and the continuous development of the keratoconjunctival lesion possibly causes irreversible influence on vision. The traditional Chinese medicine composition is characterized by being prepared from the following raw material medicines in parts by mass: 100 to 1000 parts of radix rehmanniae, 100 to 1000 parts of radix ophiopogonis, 100 to 1000 parts of herba dendrobii, 100 to 1000 parts of bulbus lilii, 100 to 1000 parts of radix polygonati officinalis and 200 to 500 parts of flos chrysanthemi. Corresponding auxiliary materials can also be added into the traditional Chinese medicine composition to prepare clinically common tablets, granules and oral dosage forms.

The invention relates to an alpha-adrenergic receptor agonist ophthalmic composition and application thereof. The composition comprises an alpha-adrenergic receptor agonist and an M choline receptor agonist. The ophthalmic composition provided by the invention can meet the requirements of different patients for improving short-distance vision and long-distance vision, and has a relatively long retention time up to 10 hours. In addition, the composition provided by the invention can quickly eliminate conjunctival congestion and asthenopia, and has a good curative effect on preventing and treating eye diseases such as presbyopia, ocular hypertension, xerophthalmia, myopia, hyperopia, strabismus, astigmatism, photophobia or glaucoma.

This invention is new because no prior art discusses using any of these antiemetics as a single entity medication or in combination with any analgesic(s) for the indication of nausea with or without vomiting; vertigo including MAV, photophobia, phonophobia, with or without pain. This invention also differs from prior art in that the aforementioned antiemetics in any combination with the aforementioned analgesic(s), are also able to combined with or without a nasal decongestant dextromethorphan guaifenesin. The interchangeability of the drugs and doses allows for versatility which prior art does not offer. Actual dosages used will be within that range at therapeutic, efficacious, and safe dosages in subjects for the treatment of the indication(s) being claimed and / or exhibited by subjects. Utilizing subtherapeutic and supratherapeutic doses in the ranges are not obvious or usual doses utilized by people knowledgeable in the prior art, differentiating it from prior art and supporting patentability.

Disclosed herein are methods of treating or preventing headaches (e.g., migraines) and / or photophobia in a subject comprising administering a pharmaceutical composition comprising one or more therapeutic agents selected from a triptan, a beta blocker, an alpha agonist, and a CORP antagonist.

The invention discloses a preparation method and application of a hydrogel material with functions of bearing and slowly releasing low-concentration atropine sulfate, and relates to the technical field of drug-loaded contact lenses. The preparation method of the hydrogel material comprises the following steps: uniformly mixing ethyl 2-hydroxymethyl acrylate, N-vinyl pyrrolidone, ethylene glycol dimethacrylate and 2-hydroxy-2-methyl-1-phenyl-1-acetone, pouring the mixture into a mold, carrying out ultraviolet polymerization, soaking the mold in a phosphate buffer solution containing atropine sulfate, and drying the mold to obtain the hydrogel material. The hydrogel material with the function of bearing and slowly releasing the low-concentration atropine sulfate is obtained. The hydrogel material prepared by the method provided by the invention has good transmittance, high water content and good biocompatibility, the refractive index and the slow release rate can be adjusted, the hydrogel material also has secondary loading-slow release capability, and the problems of photophobia, near vision, reduction of visual functions of two eyes and the like caused by existing medicines for delaying myopia are effectively solved.

An ophthalmic imaging system provides an automatic focus mechanism based on the difference of consecutive scan lines. The system also provides of user selection of a focus point within a fundus image. A neural network automatically identifies the optic nerve head in an FA or ICGA image, which may be used to determine fixation angle. The system also provides additional scan tables for multiple imaging modalities to accommodate photophobia patients and multi-spectrum imaging options.

An information processing apparatus comprises analysis circuitry to receive captured images comprising at least one eye of a user when viewing display images displayed by a head mounted display “HMD”.

A lighting device that provides a green-enriched white light. The lighting device includes one or more light sources that collectively produce light with wavelengths ranging from violet light through red light. A normalized intensity of wavelengths in a green light range of the produced light is greater than a normalized intensity of wavelengths in a blue light range of the produced light.

The invention belongs to the technical field of medical instruments, and provides a retinopathy examination device. A retinopathy examination apparatus according to the present invention comprises: an examination subject for examining retinopathy; the fixed rack is arranged at one end of the examination main body and is used for supporting and fixing the head of a patient to be examined; and the shading assembly is rotationally mounted on the inspection main body, is propped against the fixed rack and is used for shading. In conclusion, the retinopathy examination device is reasonable in design and easy to operate, the fixing effect and light shielding can be effectively achieved, photophobia of patients is reduced, and efficient and accurate examination results are achieved for diabetic patients; therefore, the device is suitable for industrial popularization.

The present invention relates to a membrane-changing multi-point defocus eyeglass lens and a preparation method thereof, comprising a rear surface protective film layer, a multi-point defocus substrate, a composite color-changing film layer, and a front surface protective film layer, which are sequentially arranged from the human eye side to the light incident side; the multi-point defocus substrate is sequentially arranged from the center to the edge as a central viewing area, a multi-point defocus area, and an edge viewing area; the front surface of the multi-point defocus area is provided with N circles of non-continuous, dot-shaped microlenses; the composite color-changing film layer is a sequentially spin-coated N+1-layer single-layer color-changing film, the first N layers of single-layer color-changing film sequentially covering each circle of microlenses, and the N+1th layer of single-layer color-changing film covering the entire front surface of the multi-point defocus substrate. The present invention adopts a membrane-changing color-changing composite multi-point defocusing function, which can not only intervene and adjust the problem of worsening myopia caused by compensatory elongation of the eye axis, but also prevent strong light from damaging the human eye, thereby achieving multiple protections for the human eye. It can be used in conjunction with atropine eye drops and can effectively alleviate adverse reactions such as photophobia caused by atropine eye drops.

The invention discloses a photoetching ultrastructure multifunctional lens for preventing and delaying myopia, which comprises a lens main body, and a functional area is arranged in the lens main body. Compared with the prior art, the ultra-micro lens has the advantages that the ultra-micro lens forms a dense negative out-of-focus signal interference area, when eyes rotate, light passing through the area can generate irregular dynamic changes in different states of convergence, divergence and the like, meanwhile, the light is diffused at gap composite points of the photoetching ultra-micro lens, and the light intensity is improved. By means of the comprehensive design, the intensity of the negative defocus signals reaching the retina can be weakened to the maximum extent, the brain is prevented from receiving the negative defocus signals possibly accelerating myopia development, and then the effect that myopia occurrence and development are delayed in a nearly non-inductive mode is achieved. For the photophobia phenomenon occurring when low-concentration atropine is used for preventing and controlling myopia, a color-changing film layer can be additionally arranged to adjust the brightness of light rays entering eyes so as to relieve symptoms.